Abstract: This application provides a short-range wireless communication method and a related device. The method includes: generating a transmission frame. The transmission frame includes a frame header and a data domain, phase shift keying modulation is used for the frame header, and quadrature amplitude modulation or phase shift keying modulation is used for the data domain. The method includes sending the transmission frame. In this application, the phase shift keying modulation is used for the frame header of the transmission frame, and the phase shift keying modulation or the quadrature amplitude modulation with a same bandwidth is used for the data domain.

Abstract: The disclosure generally pertains to systems and methods for predicting energy consumption in vehicles. In an example method, a predicted energy consumption model associated with a vehicle may be determined. Sensor data associated with the vehicle may be received via a plurality of sensors associated with the vehicle. A driver-based energy consumption model associated with the vehicle may then be determined based at least in part on the sensor data. An estimated energy consumption model associated with the vehicle may then be determined based at least in part on the predicted energy consumption model and the driver-based energy consumption model. A vehicle charging prediction model may then be determined based at least in part on the estimated energy consumption model.

Abstract: Disclosed is a method for synthesizing (S)-nicotine and an intermediate thereof, which belongs to the field of synthesizing a heterocyclic compound. A chiral amino group is introduced into 4-hydroxy-1-(3-pyridyl)-1-butanone by transaminase chiral catalysis in the presence of an amino donor to obtain (S)-4-amino-4-(3-pyridyl)-1-butanol. An N-methylation reaction is performed on (S)-4-amino-4-(3-pyridyl)-1-butanol with a methylating agent to obtain (S)-4-(methylamino)-4-(3-pyridyl)-1-butanol. The intermediate is reacted with an acylating agent or a halogenating agent to convert an alcoholic hydroxyl group into a sulfonate group or a halogen. Finally, a ring closure reaction is performed to obtain (S)-nicotine in an alkaline condition. The raw materials are cheap and readily available, the reaction conditions are mild, the operation is simple, and the cost is low.

Abstract: A method includes determining, based on a length of to-be-encoded information bits and a code rate, a code length N after encoding; determining, based on N, a minimum segment code length and a maximum segment code length, a reserved segment quantity of each type of segments in segments of b?a+1 types of segment code lengths and a reserved code length corresponding to N, where the minimum segment code length is 2{circumflex over (?)}a, and the maximum segment code length is 2{circumflex over (?)}b; determining a segment quantity of each type of segments based on N, the reserved code length, a segment code length of each type of segments, and the reserved segment quantity, where N corresponds to S segments, and a segment code length of an ith segment in the S segments is greater than or equal to a segment code length of an (i+1)th segment in the S segments.

Abstract: Provided are compositions and methods for treating cancer comprising the use of a immunoconjugate in combination with a cytotoxic agent or cytotoxic therapy. The immunoconjugate in combination with a cytotoxic agent or cytotoxic therapy shows synergistic effects in cancer treatment.

Abstract: Provided are proteinaceous heterodimers, pharmaceutical compositions, medicaments and/or kits comprising the proteinaceous heterodimers, methods for producing the proteinaceous heterodimers, and uses thereof.

Abstract: Example wireless communication methods and apparatus are described. In one example method, a Bluetooth sending apparatus generates and sends a first Bluetooth data frame to a Bluetooth receiving apparatus. The first Bluetooth data frame includes a first access code, a first synchronization code, and a first data field, and the first synchronization code is located before the first data field. When performing at least one of autocorrelation or cross-correlation, the first synchronization code provides a higher success rate of at least one of synchronization detection or data receiving than the first access code.

Abstract: The present disclosure provides an antibody, or an antigen binding fragment or variant thereof, which binds to CD27 and exhibits at least one of the following properties: specifically binds to CD27 with a KD of 10?8 M or less; activates and/or increases CD27 mediated NF-?B activity; stimulates CD4+ and/or CD8+ T cell proliferation; binds to human CD27 expressed on a cell surface; stimulates secretion of IFN-? by CD4+ and/or CD8+ T cells. The present disclosure also provides a method for preparing and using said antibody.

Abstract: Provided by the present application is a preparation, which comprises an antibody specifically bound with CD137 or an antigen-binding fragment thereof, wherein the CD137 antibody comprises a light chain variable region VL and a heavy chain variable region VH, wherein the VL comprises an amino acid sequence shown in any one of SEQ ID NO: 1-11, and the VH comprises an amino acid sequence shown in any one of SEQ ID NO:12-22. Also provided by the present application are a kit comprising the preparation, and a use of the preparation or the kit in the preparation of a drug, the drug being used for the treatment of a cancer.

Abstract: The present invention provides methods of determining a survival predictor score of a subject having mantle cell lymphoma (MCL). The present invention also provides methods of predicting the survival outcome of a subject having MCL and provides methods of selecting a treatment for a subject having MCL.

Abstract: A composition including an immunoconjugate and a chemotherapeutic agent. The immunoconjugate includes 1) one or more interleukins, and 2) an Fc domain consisting of a first Fc subunit and a second Fc subunit. The first Fc subunit associates with the second Fc subunit to form a dimer. The one or more interleukins are fused to the Fc domain and the chemotherapeutic agent includes a fluorouracil and/or an oxaliplatin.

Abstract: An iron core structure in a transformer which can show different leakage inductance values between primary and secondary windings includes an iron core, and the primary and secondary windings. A first core member of the iron core includes first and second side legs on either side of a first center leg, a second core member butted against the first includes third and fourth side legs on either side of a second center leg. The primary winding is arranged on the center leg, and the secondary winding is arranged on the side legs. The first and third side legs define a gap therebetween, there is a second gap defined between second and fourth side legs. Effective magnetic resistance of the side legs is increased, the primary and secondary windings show different leakage inductance values, and can meet diversified needs of power stage control circuits.

Abstract: In embodiments of the invention, the invention provides a method for distinguishing between lymphoma types based on gene expression measurements. In embodiments, the invention distinguishes between PMBCL and DLBCL based on gene expression signatures, and can further distinguish between DLBCL subtypes. In embodiments of the invention, the distinctions are used in methods of treatment.

Abstract: Fabricating a regrown GaN p-n junction includes depositing a n-GaN layer on a substrate including n+-GaN, etching a surface of the n-GaN layer to yield an etched surface, depositing a p-GaN layer on the etched surface, etching a portion of the n-GaN layer and a portion of the p-GaN layer to yield a mesa opposite the substrate, and passivating a portion of the p-GaN layer around an edge of the mesa. The regrown GaN p-n junction is defined at an interface between the n-GaN layer and the p-GaN layer. The regrown GaN p-n junction includes a substrate, a n-GaN layer on the substrate having an etched surface, a p-GaN layer on the etched surface, a mesa defined by an etched portion of the n-GaN layer and an etched portion of the p-GaN layer, and a passivated portion of the p-GaN layer around an edge of the mesa.

Abstract: Fabricating a vertical-channel junction field-effect transistor includes forming an unintentionally doped GaN layer on a bulk GaN layer by metalorganic chemical vapor deposition, forming a Cr/SiO2 hard mask on the unintentionally doped GaN layer, patterning a fin by electron beam lithography, defining the Cr and SiO2 hard masks by reactive ion etching, improving a regrowth surface with inductively coupled plasma etching, removing hard mask residuals, regrowing a p-GaN layer, selectively etching the p-GaN layer, forming gate electrodes by electron beam evaporation, and forming source and drain electrodes by electron beam evaporation. The resulting vertical-channel junction field-effect transistor includes a doped GaN layer, an unintentionally doped GaN layer on the doped GaN layer, and a p-GaN regrowth layer on the unintentionally doped GaN layer. Portions of the p-GaN regrowth layer are separated by a vertical channel of the unintentionally doped GaN layer.

Abstract: A control method for a reinforcement learning system includes following operations. The reinforcement learning system obtains training data relating to an interaction system. The interaction system interacts with a reinforcement learning agent. A neural network model is utilized by the reinforcement learning agent for selecting sequential actions from a set of candidate actions. The neural network model is trained to maximize cumulative rewards collected by the reinforcement learning agent in response to the sequential actions. During training of the neural network model, auxiliary rewards of the cumulative rewards are provided to the reinforcement learning agent according to a comparison between symptom inquiry actions of the sequential actions and diagnosed symptoms in the training data.

Abstract: The invention is directed to methods for selecting a treatment option for an activated B cell-like diffuse large B cell lymphoma (ABC DLBCL) subject, a germinal center B cell-like diffuse large B cell lymphoma (GCB DLBCL) subject, a primary mediastinal B cell lymphoma (PMBL) subject, a Burkitt lymphoma (BL) subject, or a mantle cell lymphoma (MCL) subject by analyzing digital gene expression data obtained from the subject, e.g., from a biopsy sample.

Abstract: Disclosed herein are methods of diagnosing and treating a subject with prostate cancer, as well as methods of monitoring the responsiveness of a subject having prostate cancer to a therapeutic agent.

Abstract: Provided is an immunoconjugate useful in inhibiting tumor growth, and a composition and/or protein mixture comprising the immunoconjugate. Also provided are methods for the production of the immunoconjugate, as well as pharmaceutical uses of the immunoconjugate in inhibiting tumor growth, including but not limited to treatment of cancers.

Abstract: A switching device including a GaN substrate; an unintentionally doped GaN layer on a first surface of the GaN substrate; a regrown unintentionally doped GaN layer on the unintentionally doped GaN layer; a regrowth interface between the unintentionally doped GaN layer and the regrown unintentionally doped GaN layer; a p-GaN layer on the regrown unintentionally doped GaN layer; a first electrode on the p-GaN layer; and a second electrode on a second surface of the GaN substrate.